Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes. (Q53389613)

13 May 2018

title

Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes. (English)

1 reference

13 May 2018

author name string

Byeong-Woo Park

1

1 reference

13 May 2018

Seho Park

2

1 reference

13 May 2018

Hyung Seok Park

3

1 reference

13 May 2018

Ja Seung Koo

4

1 reference

13 May 2018

Woo Ick Yang

5

1 reference

13 May 2018

Jun Sang Lee

6

1 reference

13 May 2018

Hyewon Hwang

7

1 reference

13 May 2018

Seung Il Kim

8

1 reference

13 May 2018

Kyong Sik Lee

9

1 reference

13 May 2018

language of work or name

English

0 references

publication date

1 June 2012

1 reference

13 May 2018

Breast Cancer Research and Treatment

published in

1 reference

13 May 2018

volume

133

1 reference

13 May 2018

issue

2

1 reference

13 May 2018

page(s)

741-751

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1007/s10549-012-1971-2

exact match

0 references

cites work

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Ki67 in breast cancer: prognostic and predictive potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Reporting recommendations for tumor marker prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Cox-2 and its association with prognostic factors and response to primary chemotherapy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

The role of cyclooxygenase-2 in breast cancer: review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-1971-2

10.1007/S10549-012-1971-2

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018